Expert panelists discuss the lack of diversity among available treatment options for MDD.
H. Eric Cannon, PharmD, FAMCP: When we look at the diversity of available treatment options and dozens of therapeutic options, most of them within several classes, it puts the clinician in a situation where many times the first 2 or 3 options are guesses. National guidelines have stated to start with an SSRI [selective serotonin reuptake inhibitor], try another if that fails, and then try another if that fails. It’s important to work with our clinicians so that they understand the benefits of each therapeutic option and try to align that with patients. They try to say, “You’re activated. Let’s try something that has more of a depressive effect that can bring you down and also help with depression,” but it’s difficult. We’re making progress. We’ve got genetic tests and a few things to help us identify opportunities for improvement, but it’s critical to have new treatments that work fast.
Michael Rothrock, MBA, MHA: The perception of the diversity of the treatment options is extremely limited. The mechanisms of action [MOAs] are fairly consistent, whether they’re SSRIs, SSNRIs [selective serotonin-norepinephrine reuptake inhibitor], or even things like old legacy TCAs [tricyclic antidepressants]. As Eric mentioned, most physicians are going to try an SSRI and titrate it up to a tolerability or, if doesn’t work, do it again with a different molecule. There aren’t a lot of efficacious options if they’ve already failed the comparable MOA they’ve previously been on. There might be some nuances in tolerability, but I don’t think the efficacy benefits are that differentiated.
Transcript edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More